Li Sufang, Zhang Feng, Cui Yuxia, Wu Manyan, Lee Chongyou, Song Junxian, Cao Chengfu, Chen Hong
Department of Cardiology, Peking University People's Hospital, Beijing, 100044, China; Beijing Key Laboratory of Early Prediction and Intervention of Acute Myocardial Infarction, Peking University People's Hospital, Beijing, 100044, China; Center for Cardiovascular Translational Research, Peking University People's Hospital, Beijing, 100044, China.
Department of Cardiology, Peking University People's Hospital, Beijing, 100044, China; Beijing Key Laboratory of Early Prediction and Intervention of Acute Myocardial Infarction, Peking University People's Hospital, Beijing, 100044, China; Center for Cardiovascular Translational Research, Peking University People's Hospital, Beijing, 100044, China.
Biochem Biophys Res Commun. 2017 Nov 4;493(1):556-561. doi: 10.1016/j.bbrc.2017.08.153. Epub 2017 Sep 1.
Heparin, a widely used anticoagulant in cardiovascular diseases, is notorious for its inhibitory effect on qRT-PCR-based detection. Heparinase I could degrade heparin in RNA. qRT-PCR-based TaqMan Low Density Array (TLDA) technology is commonly used for circulating microRNAs (miRNAs) profiling analysis. However, the effect of heparin contamination on inhibition of miRNAs TLDA amplification, as well as the method for removing heparin during this process, are not yet well investigated. We obtained the plasma RNA samples from patients undergoing percutaneous coronary intervention (PCI) before and after heparinization (n = 26). We found that heparin suppressed the miRNAs amplification by ∼8 cycles in the TLDA assay, which was absolutely reversed after treating the RNA samples with heparinase I using the components from TLDA reverse transcription system. We further observed that heparin inhibited the miRNAs amplification by ∼4 cycles in the qRT-PCR assay, which was also reversed by heparinase I using the similar method. Furthermore, we demonstrated that plasma miR-92a and miR-155 were differentially expressed in the patients undergoing PCI tested by TLDA assay, which was validated by qRT-PCR. In conclusion, we present a simple method for the removal of heparin with heparinase I, and for the subsequent successful miRNAs TLDA or RT-qPCR amplification.
肝素是心血管疾病中广泛使用的抗凝剂,因其对基于定量逆转录聚合酶链反应(qRT-PCR)的检测具有抑制作用而声名狼藉。肝素酶I可以降解RNA中的肝素。基于qRT-PCR的TaqMan低密度阵列(TLDA)技术通常用于循环微小RNA(miRNA)谱分析。然而,肝素污染对miRNA TLDA扩增的抑制作用,以及在此过程中去除肝素的方法,尚未得到充分研究。我们获取了26例接受经皮冠状动脉介入治疗(PCI)的患者在肝素化前后的血浆RNA样本。我们发现,在TLDA检测中,肝素使miRNA扩增抑制约8个循环,而使用TLDA逆转录系统的成分用肝素酶I处理RNA样本后,这种抑制作用完全逆转。我们进一步观察到,在qRT-PCR检测中,肝素使miRNA扩增抑制约4个循环,使用类似方法也可被肝素酶I逆转。此外,我们证明,通过TLDA检测,血浆miR-92a和miR-155在接受PCI的患者中差异表达,这通过qRT-PCR得到验证。总之,我们提出了一种用肝素酶I去除肝素的简单方法,以及随后成功进行miRNA TLDA或逆转录定量聚合酶链反应(RT-qPCR)扩增的方法。